ClinicalTrials.gg

Program

Tirapazamine

Also written as “tirapazamine” and “tirapazamine (SR259075)”.

Its studies are mostly in Carcinoma, Hepatocellular · Squamous Cell Carcinoma of Head and Neck · Carcinoma, Non-Small-Cell Lung · Head and Neck Neoplasms, led by 3 companies.

Furthest: phase 3, since Jun 6, 20017 company-led studies, 2 open or runningNext primary completion: Mar 31, 2028 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sanofi30 open or runningphase 3since Jun 6, 2001Jun 6, 2001none ahead
Teclison21 open or runningphase 2since Jun 10, 2014Jun 10, 2014Mar 31, 2028phase 2 · NCT02174549
Zhejiang Raygene Pharmaceuticals21 open or runningphase 3since Feb 19, 2025Feb 19, 2025Apr 1, 2029phase 3 · NCT06844357

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 6, 2001First study: phase 3 study in Lung NeoplasmsNew to SanofiSanofi · NCT00017459 · United States
  2. Oct 11, 2004Phase 3 study in Head and Neck NeoplasmsSanofi · NCT00094081 · 861 enrolled · United States
  3. Sep 13, 2005Phase 3 study in Squamous Cell Carcinoma of Head and NeckSanofi · NCT00174837 · 317 enrolled · United States, Argentina, Australia and more
  4. Jun 10, 2014Teclison's first study: phase 2 study in Carcinoma, HepatocellularNew to TeclisonTeclison · NCT02174549 · 25 planned · United States
  5. May 3, 2017Phase 2 study in Carcinoma, HepatocellularTeclison · NCT03145558 · 6 enrolled · United States
  6. Feb 19, 2025Zhejiang Raygene Pharmaceuticals's first study: phase 2 study in Carcinoma, HepatocellularNew to Zhejiang Raygene PharmaceuticalsZhejiang Raygene Pharmaceuticals · NCT06848556 · 16 enrolled · China
  7. Feb 19, 2025Phase 3 study in HCCZhejiang Raygene Pharmaceuticals · NCT06844357 · 300 planned · China

Ahead

  1. Mar 31, 2028Primary completion: phase 2 study in Carcinoma, HepatocellularTeclison · NCT02174549
  2. Apr 1, 2029Primary completion: phase 3 study in HCCZhejiang Raygene Pharmaceuticals · NCT06844357

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 7 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT06848556Carcinoma, Hepatocellular · China2TerminatedZhejiang Raygene PharmaceuticalsNov 6, 202316
NCT06844357HCC · China3RecruitingZhejiang Raygene PharmaceuticalsApr 1, 2029300
NCT03145558Carcinoma, Hepatocellular · United States2TerminatedTeclisonJun 30, 20246
NCT02174549Carcinoma, Hepatocellular · United States2RecruitingTeclisonMar 31, 202825
NCT00174837Squamous Cell Carcinoma of Head and Neck · United States, Argentina, Australia and more3CompletedSanofiJan 2008317
NCT00094081Head and Neck Neoplasms · United States3CompletedSanofiSep 2006861
NCT00017459Lung Neoplasms · United States3CompletedSanofi

How it is read

Names in the registry

  • “Tirapazamine”, 3 entries
  • “tirapazamine”, 3 entries
  • “tirapazamine (SR259075)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.